ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.65
0.48%
US Tech 100
18,318.00
0.95%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36715
-0.04%
Bitcoin
69,010.72
0.70%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Qualigen Therapeutics Inc (QLGN)

  7. Qualigen Therapeutics Inc (QLGN) News

QLGN

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:QLGN
DateTimeSourceHeadlineSymbolCompany
05/14/20243:05PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:QLGNQualigen Therapeutics Inc
05/03/20247:59PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
04/16/20246:00AMGlobeNewswire Inc.Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™NASDAQ:QLGNQualigen Therapeutics Inc
04/10/20247:00AMGlobeNewswire Inc.Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
04/09/20247:00AMGlobeNewswire Inc.Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
02/27/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
02/22/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
12/07/20233:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
11/22/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
11/14/20233:30PMGlobeNewswire Inc.Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023NASDAQ:QLGNQualigen Therapeutics Inc
11/08/20231:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
11/07/20237:30AMGlobeNewswire Inc.Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
10/23/20237:30AMGlobeNewswire Inc.Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerNASDAQ:QLGNQualigen Therapeutics Inc
10/17/20237:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
09/28/20233:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
09/27/20237:30AMGlobeNewswire Inc.Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023NASDAQ:QLGNQualigen Therapeutics Inc
09/07/202311:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QLGNQualigen Therapeutics Inc
09/01/20233:15PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:QLGNQualigen Therapeutics Inc
08/17/20237:30AMGlobeNewswire Inc.Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
08/15/20239:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
08/15/20237:30AMGlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/14/20233:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QLGNQualigen Therapeutics Inc
08/04/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
08/01/20237:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
08/01/20237:30AMGlobeNewswire Inc.Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
07/26/20234:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/24/20237:15AMGlobeNewswire Inc.Qualigen Therapeutics Divests FastPack® Diagnostics BusinessNASDAQ:QLGNQualigen Therapeutics Inc
07/13/20234:29PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/07/20234:08PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
06/26/20234:25PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QLGNQualigen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QLGN

Your Recent History

USOTC
DPLS
DarkPulse (PK)
USOTC
CNNA
Cann American (CE)
USOTC
CYDY
CytoDyn (QB)
USOTC
BIEL
Bioelectronics (PK)
USOTC
SHMP
NaturalShrimp (QB)
NASDAQ
AGBA
AGBA
AMEX
SPY
SPDR S&P 500
USOTC
BMXI
Brookmount Explorations (PK)
NASDAQ
RNAZ
TransCode Therapeutics
NASDAQ
DJT
Trump Media and Technology
USOTC
UBQU
Ubiquitech Software (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
AHRO
Authentic (CE)
USOTC
TDRK
TideRock Companies (PK)
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved